The introduction of chlorpromazine in Belgium and the Netherlands (1951-1968); tango between old and new treatment features.

Stud Hist Philos Biol Biomed Sci

Descartes Centre for the History and Philosophy of the Sciences and the Humanities/Department of Pharmaceutical Sciences, University of Utrecht, The Netherlands.

Published: December 2011

The introduction of chlorpromazine in Belgium and the Netherlands demonstrates an intriguing tango between old and new treatments. Chlorpromazine, marketed by the French company Rhône Poulenc entered psychiatry as an adjunct to existing therapies. Instead of promoting chlorpromazine as a revolutionary therapy, we see early efforts to market Largactil as a supplement to the armoury of psychiatric treatments. These marketing efforts matched the idiosyncrasies of national and local styles and cultures. Despite continuities with earlier therapeutic developments, we support the notion of a therapeutic revolution. In the early sixties supply and demand provoked a turn towards more standardized therapeutic regimes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.shpsc.2011.05.003DOI Listing

Publication Analysis

Top Keywords

introduction chlorpromazine
8
chlorpromazine belgium
8
belgium netherlands
8
netherlands 1951-1968
4
1951-1968 tango
4
tango treatment
4
treatment features
4
features introduction
4
netherlands demonstrates
4
demonstrates intriguing
4

Similar Publications

Early Treatment-Resistance in First Episode Psychosis.

Pharmacopsychiatry

November 2024

Department of Psychiatry and Psychotherapy, Bezirkskrankenhaus Schwaben, Universitätsklinikum Augsburg, Augsburg, Germany.

Introduction: Approximately 30% of individuals with schizophrenia experience treatment resistance (TR), with 70% exhibiting it from the onset. Most research fails to distinguish between acquired and innate resistance, with limited data on TR in first episode psychosis (FEP). However, FEP patients with TR experience progressively worse outcomes compared to those with initial response.

View Article and Find Full Text PDF

A Pharmacovigilance Study on Psychotropic Agent-Induced Urinary Retention Using the Japanese Adverse Drug Event Report Database.

Drugs Real World Outcomes

December 2024

Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.

Introduction: Psychotropic drugs have been reported to cause urinary retention (UR) via anticholinergic and other mechanisms. However, UR has not received much attention because of its non-fatal symptoms. We investigated the occurrence of UR associated with psychotropic drugs using the Japanese Adverse Drug Event Report (JADER) database.

View Article and Find Full Text PDF

CEPHALIC TETANUS: A CASE REPORT AND REVIEW OF LITERATURE.

West Afr J Med

November 2024

Paediatric Infectious Diseases Unit, Department of Paediatrics, Jos University Teaching Hospital/University of Jos, Jos, Plateau State, Nigeria.

Summary/introduction: Cephalic tetanus (CT) constitutes only 1-3% of total reported tetanus cases. It is marked by flaccid paralysis of one or more cranial nerves (CN) with or without spasticity, typically following craniofacial injuries. The facial nerve is the most frequently paralyzed.

View Article and Find Full Text PDF

Introduction: Antipsychotic psychopharmacotherapy is associated with the risk of drug-induced liver injury (DILI). However, understanding specific risk factors remains challenging due to limited data. This study investigates the relationship between receptor binding affinities and occupancies of antipsychotics and their associated hepatotoxic risks.

View Article and Find Full Text PDF

Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.

Am J Psychiatry

October 2024

Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Munich (Leucht, Priller); German Center for Mental Health, Munich (Leucht, Priller); Neuropsychiatry, Charité-Universitätsmedizin Berlin, and German Center for Neurodegenerative Disorders, Berlin (Priller); University of Edinburgh and UK Dementia Research Institute, Edinburgh (Priller); Department of Psychiatry, University of Illinois at Chicago (Davis).

The introduction of the first antipsychotic drug, chlorpromazine, was a milestone for psychiatry. The authors review the history, classification, indications, mechanism, efficacy, side effects, dosing, drug initiation, switching, and other practical issues and questions related to antipsychotics. Classifications such as first-generation/typical versus second-generation/atypical antipsychotics are neither valid nor useful; these agents should be described according to the Neuroscience-based Nomenclature (NbN).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!